Huiyu Pharmaceutical: The clinical trial application for injection HY07121 for the treatment of advanced solid tumors has been accepted.

Huayu Pharmaceutical announced that its wholly-owned subsidiary, Sichuan Huayu Haiyue Medical Technology Co., Ltd., recently received a "Notice of Acceptance" issued by the National Medical Products Administration for its clinical trial application for injection HY07121 for the treatment of advanced solid tumors. Injection HY07121 is an anti-PD-1, anti-TIGIT, IL-15/IL-15R bispecific fusion protein independently developed by the company's wholly-owned subsidiary, Huayu Haiyue. Its registration classification is a Class 1 innovative biological product for therapeutic use.